{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:27:25Z","timestamp":1787117245088,"version":"build-2736575974"},"reference-count":157,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Medicinal Research Reviews"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The saturated five\u2010membered pyrrolidine ring is a privileged scaffold in medicinal chemistry. There is great interest in the pyrrolidine skeleton due to several key characteristics of this heterocyclic ring: its sp\n                    <jats:sup>3<\/jats:sup>\n                    hybridized carbon framework, the contribution of multiple chiral centers, and the inherent planarization of the ring, typically manifested as conformational flexibility or pseudorotation. These characteristics make pyrrolidine\u2010based structures highly attractive in the drug design for various biological targets. The pyrrolidine moiety also enhances drug\u2010like properties such as metabolic stability, water solubility, and modulation of basicity, and can interact favorably with a wide range of biological targets through specific stereochemical interactions. This review surveys the synthesis and clinical applications of FDA\u2010approved pyrrolidine\u2010containing drugs since 2014, with the aim of informing the rational design of next\u2010generation pyrrolidine\u2010based therapeutics.\n                  <\/jats:p>","DOI":"10.1002\/med.70100","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:07:31Z","timestamp":1787116051000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Application of Pyrrolidine in FDA\u2010Approved Drugs"],"prefix":"10.1002","author":[{"given":"Jiao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Anesthesiology The First Hospital of China Medical University Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Shengjing Hospital of China Medical University Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Shengjing Hospital of China Medical University Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatao","family":"Wang","sequence":"additional","affiliation":[{"name":"Rega Institute of Medical Research, KU Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Shengjing Hospital of China Medical University Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Shengjing Hospital of China Medical University Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2541-3795","authenticated-orcid":false,"given":"Qifang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Shengjing Hospital of China Medical University Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"issue":"6","key":"e_1_2_7_2_1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/antibiotics9060292","article-title":"New Synthetic Nitro\u2010Pyrrolomycins as Promising Antibacterial and Anticancer Agents","volume":"9","author":"Raimondi M. V.","year":"2020","journal-title":"Antibiotics (USSR)"},{"issue":"20","key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"12023","DOI":"10.1021\/acs.jmedchem.0c01315","article-title":"Pyrrolo[2\u2019,3\u2019:3,4]cyclohepta[1,2\u2010d][1,2]oxazoles, a New Class of Antimitotic Agents Active Against Multiple Malignant Cell Types","volume":"63","author":"Span\u00f2 V.","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s13596-019-00419-4","article-title":"Pyrrolidine Alkaloids and Their Promises in Pharmacotherapy","volume":"20","author":"Islam M. T.","year":"2020","journal-title":"Advances in Traditional Medicine"},{"issue":"5","key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s41061-021-00347-5","article-title":"Pyrrolidine in Drug Discovery: A Versatile Scaffold for Novel Biologically Active Compounds","volume":"379","author":"Li Petri G.","year":"2021","journal-title":"Topics in Current Chemistry"},{"issue":"21","key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape From Flatland: Increasing Saturation as an Approach To Improving Clinical Success","volume":"52","author":"Lovering F.","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/cbdd.12260","article-title":"Two\u2010 and Three\u2010Dimensional Rings in Drugs","volume":"83","author":"Aldeghi M.","year":"2014","journal-title":"Chemical Biology & Drug Design"},{"issue":"1","key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drudis.2014.09.023","article-title":"Designing Novel Building Blocks Is an Overlooked Strategy to Improve Compound Quality","volume":"20","author":"Goldberg F. W.","year":"2015","journal-title":"Drug Discovery Today"},{"issue":"9","key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1039\/c2md20111a","article-title":"The Developability of Heteroaromatic and Heteroaliphatic Rings\u2014Do Some Have a Better Pedigree as Potential Drug Molecules Than Others?","volume":"3","author":"Ritchie T. J.","year":"2012","journal-title":"MedChemComm"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fphar.2023.1239658","article-title":"Recent Insights about Pyrrolidine Core Skeletons in Pharmacology","volume":"14","author":"Poyraz S.","year":"2023","journal-title":"Frontiers in Pharmacology"},{"issue":"10","key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1039\/D5MD00403A","article-title":"Analysis of the Structural Diversity of Heterocycles amongst European Medicines Agency Approved Pharmaceuticals (2014\u20102023)","volume":"16","author":"Ward M.","year":"2025","journal-title":"RSC Medicinal Chemistry"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.2147\/DDDT.S77760","article-title":"Eliglustat Tartrate for the Treatment of Adults With Type 1 Gaucher Disease","volume":"9","author":"Bennett L.","year":"2015","journal-title":"Drug Design, Development and Therapy"},{"issue":"15","key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s40265-014-0296-3","article-title":"Eliglustat: First Global Approval","volume":"74","author":"Poole R. M.","year":"2014","journal-title":"Drugs"},{"key":"e_1_2_7_14_1","unstructured":"X.Xu Inventor; Suzhou Miracpharma Technology Co. Ltd. assignee. Preparation Method of Eliglustat for Treatment of Type\u2010I Gaucher Disease via Henry Reaction Nitroreduction and Amidation Reaction. US patent CN1045578512015."},{"issue":"2","key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40265-018-0864-z","article-title":"Ledipasvir\/Sofosbuvir: A Review in Chronic Hepatitis C","volume":"78","author":"Scott L. J.","year":"2018","journal-title":"Drugs"},{"issue":"4","key":"e_1_2_7_16_1","first-page":"256","article-title":"Ledipasvir\/Sofosbuvir (Harvoni): Improving Options for Hepatitis C Virus Infection","volume":"40","author":"Gritsenko D.","year":"2015","journal-title":"P & T"},{"issue":"20","key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV Without Cirrhosis","volume":"370","author":"Kowdley K. V.","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection","volume":"370","author":"Afdhal N.","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_7_19_1","unstructured":"H.Guo D.Kato T. A.Kirschberg et al. Inventors; Gilead Sciences Inc. Kim Choung U. assignee. Preparation of Biaryls Arylheteroaryls Heteroaryls Biarylacetylenes and Related Compounds End\u2010Capped with Amino Acid or Peptide Derivatives as Antiviral Agents. US patent WO20101326012010."},{"issue":"10","key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40262-017-0518-4","article-title":"Clinical Pharmacokinetics of Ombitasvir","volume":"56","author":"Badri P. S.","year":"2017","journal-title":"Clinical Pharmacokinetics"},{"key":"e_1_2_7_21_1","first-page":"142","article-title":"Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All\u2010Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection","volume":"8","author":"Raedler L. A.","year":"2015","journal-title":"American Health & Drug Benefits"},{"key":"e_1_2_7_22_1","unstructured":"D. A.DeGoey W. M.Kati C. W.Hutchins et al. Inventors; Abbott Laboratories assignee. Heterocyclic Compounds as Antiviral Agents and Their Preparation and Use in the Treatment of Hepatitis C Virus Infection. US patent WO20101446462010."},{"key":"e_1_2_7_23_1","unstructured":"D. A.DeGoey W. M.Kati C. W.Hutchins et al. Inventors; Abbott Laboratories AbbVie Inc. assignee. Heterocyclic Peptide Compounds as Antiviral Agents and Their Preparation and Use in the Treatment of Hepatitis C Virus Infection. US patent US201200041962012."},{"issue":"5","key":"e_1_2_7_24_1","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm401398x","article-title":"Discovery of ABT\u2010267, a Pan\u2010Genotypic Inhibitor of HCV NS5A","volume":"57","author":"DeGoey D. A.","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6","key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40265-015-0384-z","article-title":"Finafloxacin: First Global Approval","volume":"75","author":"McKeage K.","year":"2015","journal-title":"Drugs"},{"issue":"4","key":"e_1_2_7_26_1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02328-17","article-title":"Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients With Complicated Urinary Tract Infections","volume":"62","author":"Taubert M.","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"12","key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/antibiotics10121506","article-title":"Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline","volume":"10","author":"Kocsis B.","year":"2021","journal-title":"Antibiotics (USSR)"},{"issue":"4","key":"e_1_2_7_28_1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02317-17","article-title":"Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin Versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections","volume":"62","author":"Wagenlehner F.","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"e_1_2_7_29_1","unstructured":"M.Matzke U.Petersen T.Jaetsch et al. Inventors; Bayer A.\u2010G. assignee. Preparation of 7\u2010(2\u2010oxa\u20105 8\u2010diazabicyclo[4.3.0]non\u20108\u2010yl)Quinolone\u2010 and \u2010Naphthyridonecarboxylic Acid Derivatives for Therapy of Helicobacter Pylori Infections and Associated Gastroduodenal Illnesses. US patent DE196522391998."},{"issue":"8","key":"e_1_2_7_30_1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40262-017-0624-3","article-title":"Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics","volume":"57","author":"Gandhi Y.","year":"2018","journal-title":"Clinical Pharmacokinetics"},{"issue":"10","key":"e_1_2_7_31_1","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/cid\/ciz628","article-title":"SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low\u2010Cost, Fixed\u2010Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial","volume":"70","author":"Merat S.","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"e_1_2_7_32_1","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir Plus Sofosbuvir for HCV in Patients Coinfected with HIV\u20101","volume":"373","author":"Wyles D. L.","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_7_33_1","unstructured":"C.Thibeault P. J.Edwards C.Kuhn B.Moreau M.Poirier andS.Surprenant Inventors; Boehringer Ingelheim International GmbH assignee. Preparation of Biphenyls End\u2010Capped with Peptide Derivatives as Inhibitors of HCV NS5A for the Treatment of Hepatitis C Viral Infection. US patent WO20120484212012."},{"issue":"16","key":"e_1_2_7_34_1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s40265-015-0485-8","article-title":"Rolapitant: First Global Approval","volume":"75","author":"Syed Y. Y.","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"e_1_2_7_35_1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.17925\/EOH.2017.13.02.120","article-title":"Rolapitant in the Current Management of Chemotherapy\u2010Induced Nausea and Vomiting","volume":"13","author":"Rapoport B.","year":"2017","journal-title":"European Oncology & Haematology"},{"issue":"15","key":"e_1_2_7_36_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.9638","article-title":"Phase 3 Trial Results for Rolapitant, a Novel NK\u20101 Receptor Antagonist, in the Prevention of Chemotherapy\u2010Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)","volume":"32","author":"Rapoport B. L.","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"e_1_2_7_37_1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(15)00034-0","article-title":"Safety and Efficacy of Rolapitant for Prevention of Chemotherapy\u2010Induced Nausea and Vomiting After Administration of Moderately Emetogenic Chemotherapy or Anthracycline and Cyclophosphamide Regimens in Patients With Cancer: A Randomised, Active\u2010Controlled, Double\u2010Blind, Phase 3 Trial","volume":"16","author":"Schwartzberg L. S.","year":"2015","journal-title":"Lancet Oncology"},{"key":"e_1_2_7_38_1","unstructured":"Z.Tian X.Qi X.Hu et al. Inventors; Qilu Pharmaceutical Co. Ltd. assignee. Process for the Preparation of NK\u20101 Receptor Antagonist (5S 8S)\u20108\u2010[[[1(R)\u2010(3 5\u2010Bis(Trifluoromethyl)Phenyl]Ethoxy]Methyl]\u20108\u2010Phenyl\u20101 7\u2010Diazaspiro[4 5]Decan\u20102\u2010One and Its Intermediate. US patent CN1050172512015."},{"issue":"2","key":"e_1_2_7_39_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/17474124.2020.1715209","article-title":"Trifluridine\/Tipiracil for the Treatment of Metastatic Gastric Cancer","volume":"14","author":"Kawazoe A.","year":"2020","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"18","key":"e_1_2_7_40_1","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer","volume":"388","author":"Prager G. W.","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_7_41_1","unstructured":"Y.Zhen Z.Zhang Z.Zheng andN.Li Inventors; Jinan Bestcomm Pharmaceutical R & D Co. Ltd. assignee. Process for the Preparation of 5\u2010Chloro\u20106\u2010[(2\u2010Imino\u20101\u2010Pyrrolidinyl)Methyl]\u20102 4(1H 3H)\u2010Pyrimidinedione Hydrochloride. US patent CN1039802532014."},{"issue":"5","key":"e_1_2_7_42_1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40265-016-0558-3","article-title":"Elbasvir\/Grazoprevir: First Global Approval","volume":"76","author":"Keating G. M.","year":"2016","journal-title":"Drugs"},{"issue":"16","key":"e_1_2_7_43_1","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1021\/ol401864t","article-title":"Development of a Practical, Asymmetric Synthesis of the Hepatitis C Virus Protease Inhibitor MK\u20105172","volume":"15","author":"Kuethe J.","year":"2013","journal-title":"Organic Letters"},{"key":"e_1_2_7_44_1","article-title":"Elbasvir\/Grazoprevir: A Review of the Latest Agent in the Fight Against Hepatitis C","volume":"2016","author":"Bell A. M.","year":"2016","journal-title":"International Journal of Hepatology"},{"key":"e_1_2_7_45_1","doi-asserted-by":"crossref","DOI":"10.1177\/2333721418817398","article-title":"Efficacy and Safety of Elbasvir\/Grazoprevir in Hepatitis C Virus GT1\u2010 and GT4\u2010Infected People Aged 65 Years or Older","volume":"5","author":"Flamm S.","year":"2019","journal-title":"Gerontology and Geriatric Medicine"},{"issue":"11","key":"e_1_2_7_46_1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S2468-1253(17)30159-0","article-title":"Safety and Efficacy of an 8\u2010Week Regimen of Grazoprevir Plus Ruzasvir Plus Uprifosbuvir Compared With Grazoprevir Plus Elbasvir Plus Uprifosbuvir in Participants Without Cirrhosis Infected With Hepatitis C Virus Genotypes 1, 2, or 3 (C\u2010CREST\u20101 and C\u2010CREST\u20102, Part A): Two Randomised, Phase 2, Open\u2010Label Trials","volume":"2","author":"Gane E. J.","year":"2017","journal-title":"Lancet Gastroenterology & Hepatology"},{"key":"e_1_2_7_47_1","unstructured":"I.Mangion C.\u2010Y.Chen I.Jeon et al. Inventors; Merck Sharp & Dohme Corp. assignee. Process for Preparing HCV NS5A Inhibitor Tetracyclic Heterocycle Compounds End\u2010Capped with Peptides. US patent WO20150658212015."},{"issue":"5","key":"e_1_2_7_48_1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-018-0895-5","article-title":"Sofosbuvir\/Velpatasvir\/Voxilaprevir: A Review in Chronic Hepatitis C","volume":"78","author":"Heo Y. A.","year":"2018","journal-title":"Drugs"},{"key":"e_1_2_7_49_1","unstructured":"K. M.Allan S.Fujimori L. V.Heumann et al. Inventors; Gilead Pharmasset LLC assignee. Processes for Preparing Peptide Analog as Antiviral Agent. US patent WO20151914372015."},{"key":"e_1_2_7_50_1","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2147\/IDR.S171338","article-title":"Profile of Sofosbuvir\/Velpatasvir\/Voxilaprevir in the Treatment of Hepatitis C","volume":"12","author":"Childs\u2010Kean L. M.","year":"2019","journal-title":"Infect Drug Resist\u200c"},{"issue":"22","key":"e_1_2_7_51_1","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"376","author":"Bourli\u00e8re M.","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_7_52_1","unstructured":"Q.Ren L.Chen Y.Shan et al. Inventors; Sunshine Lake Pharma Co. Ltd. assignee. Preparation of Salts of a Macrocyclic Peptidomimetic as HCV Inhibitors. US patent WO20180286342018."},{"key":"e_1_2_7_53_1","unstructured":"K.Bjornson K. K.Karki J. O.Link et al. Inventors; Gilead Sciences Inc. assignee. Preparation of Macrocyclic and Bicyclic Derivatives of N\u2010Prolyl\u20101\u2010Aminocyclopropanecarboxylic Acid Peptides as Inhibitors of Hepatitis C Virus. US patent WO20141450952014."},{"issue":"16","key":"e_1_2_7_54_1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-017-0817-y","article-title":"Glecaprevir\/Pibrentasvir: First Global Approval","volume":"77","author":"Lamb Y. N.","year":"2017","journal-title":"Drugs"},{"issue":"3","key":"e_1_2_7_55_1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12072-018-9873-y","article-title":"Glecaprevir\/Pibrentasvir Expands Reach While Reducing Cost and Duration of Hepatitis C Virus Therapy","volume":"12","author":"Abutaleb A.","year":"2018","journal-title":"Hepatology International"},{"key":"e_1_2_7_56_1","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.2147\/DDDT.S172512","article-title":"Glecaprevir\/Pibrentasvir for the Treatment of Chronic Hepatitis C: Design, Development, and Place in Therapy","volume":"13","author":"Cotter T. G.","year":"2019","journal-title":"Drug Design, Development and Therapy"},{"issue":"1","key":"e_1_2_7_57_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31841","article-title":"Pharmacokinetics, Safety, and Efficacy of Glecaprevir\/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study","volume":"74","author":"Jonas M. M.","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"e_1_2_7_58_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0018578717746417","article-title":"Formulary Drug Reviews: Glecaprevir\/Pibrentasvir","volume":"53","author":"Levien T. L.","year":"2018","journal-title":"Hospital Pharmacy"},{"issue":"2","key":"e_1_2_7_59_1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.30840","article-title":"Pharmacokinetics, Safety, and Efficacy of Glecaprevir\/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study","volume":"71","author":"Jonas M. M.","year":"2020","journal-title":"Hepatology"},{"issue":"9","key":"e_1_2_7_60_1","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1021\/acs.jmedchem.8b00082","article-title":"Highlights of the Structure\u2010Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT\u2010530)","volume":"61","author":"Wagner R.","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"e_1_2_7_61_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40265-017-0852-8","article-title":"Acalabrutinib: First Global Approval","volume":"78","author":"Markham A.","year":"2018","journal-title":"Drugs"},{"key":"e_1_2_7_62_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.668162","article-title":"Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B\u2010Cell Malignancies","volume":"11","author":"Abbas H. A.","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"2","key":"e_1_2_7_63_1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors Targeting Bruton's Tyrosine Kinase in Cancers: Drug Development Advances","volume":"35","author":"Wen T.","year":"2021","journal-title":"Leukemia"},{"key":"e_1_2_7_64_1","unstructured":"X.Xu \u201cInventor; Suzhou Miracpharma Technology Co \u201d Ltd. assignee. Process for the Preparation of Acalabrutinib. 2017 US patent CN107056786."},{"issue":"11","key":"e_1_2_7_65_1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","article-title":"Alpelisib: First Global Approval","volume":"79","author":"Markham A.","year":"2019","journal-title":"Drugs"},{"issue":"16","key":"e_1_2_7_66_1","article-title":"EPIK\u2010B5: A Phase III, Randomized Study of Alpelisib (ALP) Plus Fulvestrant (FUL) in Patients With Hormone Receptor\u2010Positive (HR+), Human Epidermal Growth Factor Receptor 2\u2010Negative (HER2\u2010), PIK3CA\u2010Mutated Advanced Breast Cancer (ABC) Progressing On\/After An Aromatase Inhibitor (AI) With a Cyclin\u2010Dependent Kinase 4\/6 Inhibitor (CDK4\/6i)","volume":"40","author":"De Laurentiis M.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_7_67_1","unstructured":"EPIK\u2010O: A Phase III Multi\u2010center Randomized (1:1) Open\u2010label Active\u2010controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy in Participants With no Germline BRCA Mutation Detected Platinum\u2010resistant or Refractory High\u2010grade Serous Ovarian Cancer. 2021 https:\/\/clinicaltrials.gov\/study\/NCT04729387."},{"key":"e_1_2_7_68_1","unstructured":"B.Erb I. S.Gallou andF. K.Kleinbeck Inventors; Novartis AG Novartis Pharma AG assignee. Synthesis of 2\u2010Carboxamide Cycloamino Urea Derivatives. US patent US201303315792013."},{"issue":"2","key":"e_1_2_7_69_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: First Global Approval","volume":"79","author":"Scott L. J.","year":"2019","journal-title":"Drugs"},{"issue":"10","key":"e_1_2_7_70_1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/17512433.2019.1661775","article-title":"Larotrectinib, a Highly Selective Tropomyosin Receptor Kinase (TRK) Inhibitor for the Treatment of TRK Fusion Cancer","volume":"12","author":"Federman N.","year":"2019","journal-title":"Expert Review of Clinical Pharmacology"},{"issue":"4","key":"e_1_2_7_71_1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in Patients With TRK Fusion\u2010Positive Solid Tumours: A Pooled Analysis of Three Phase 1\/2 Clinical Trials","volume":"21","author":"Hong D. S.","year":"2020","journal-title":"Lancet Oncology"},{"key":"e_1_2_7_72_1","unstructured":"M.Ji H.Liu X.Zong et al. Inventors; Suzhou Southeast Pharmaceuticals Co. Ltd. assignee. Preparation Method and Intermediate of Larotrectinib. US patent CN1079870822018."},{"issue":"10","key":"e_1_2_7_73_1","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10096-019-03590-3","article-title":"Eravacycline, a Newly Approved Fluorocycline","volume":"38","author":"Lee Y. R.","year":"2019","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"3","key":"e_1_2_7_74_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","article-title":"Eravacycline: A Review in Complicated Intra\u2010Abdominal Infections","volume":"79","author":"Scott L. J.","year":"2019","journal-title":"Drugs"},{"issue":"5","key":"e_1_2_7_75_1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent","volume":"76","author":"Zhanel G. G.","year":"2016","journal-title":"Drugs"},{"issue":"6","key":"e_1_2_7_76_1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections","volume":"69","author":"Solomkin J. S.","year":"2019","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"e_1_2_7_77_1","article-title":"Eravacycline, the First Four Years: Health Outcomes and Tolerability Data for 19 Hospitals in 5 U.S. Regions from 2018 to 2022","volume":"12","author":"Kunz Coyne A. J.","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"5","key":"e_1_2_7_78_1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1021\/op4000219","article-title":"Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development","volume":"17","author":"Ronn M.","year":"2013","journal-title":"Organic Process Research & Development"},{"issue":"15","key":"e_1_2_7_79_1","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40265-019-01205-x","article-title":"Fedratinib: First Approval","volume":"79","author":"Blair H. A.","year":"2019","journal-title":"Drugs"},{"issue":"8","key":"e_1_2_7_80_1","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/bloodadvances.2024015365","article-title":"Fedratinib in 2025 and Beyond: Indications and Future Applications","volume":"9","author":"Coltoff A.","year":"2025","journal-title":"Blood Advances"},{"key":"e_1_2_7_81_1","unstructured":"J. J.Cao J.Hood D.Lohse et al. \u201cInventors; TargeGen Inc. assignee. Preparation of Bi\u2010aryl 2 4\u2010Pyrimidinediamines as Inhibitors of Kinases \u201d US patent WO 20070534522007."},{"key":"e_1_2_7_82_1","unstructured":"J. D.HoodandG.Noronha Inventors; TargeGen Inc. assignee. Preparation of Bi\u2010aryl 2 4\u2010Pyrimidinediamines as Inhibitors of Kinases. US patent US200902867892009."},{"key":"e_1_2_7_83_1","unstructured":"G.Noronha C. C.Mak J.Cao et al. Inventors; TargeGen Inc. assignee. Preparation of Bi\u2010aryl 2 4\u2010Pyrimidinediamines as Inhibitors of Kinases. US patent US200702599042007."},{"issue":"16","key":"e_1_2_7_84_1","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","article-title":"Upadacitinib: First Approval","volume":"79","author":"Duggan S.","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"e_1_2_7_85_1","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of Action, Clinical, and Translational Science","volume":"17","author":"Mohamed M. E. F.","year":"2024","journal-title":"Clinical and Translational Science"},{"key":"e_1_2_7_86_1","unstructured":"J. W.Voss H. S.Camp andR. J.Padley Inventors; AbbVie Inc. assignee. JAK1 Selective Inhibitor for Treatment of Inflammatory and Autoimmune Diseases. US patent WO20150616652015."},{"key":"e_1_2_7_87_1","unstructured":"N.Wishart M. A.Argiriadi D. J.Calderwood et al. Inventors; Abbott Laboratories assignee. Preparation of Novel Nitrogen\u2010Containing Tricyclic Compounds as Kinase Inhibitors. US patent US201103114742011."},{"issue":"18","key":"e_1_2_7_88_1","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s40265-019-01233-7","article-title":"Elexacaftor\/Ivacaftor\/Tezacaftor: First Approval","volume":"79","author":"Hoy S. M.","year":"2019","journal-title":"Drugs"},{"issue":"8","key":"e_1_2_7_89_1","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/17460441.2020.1750592","article-title":"The Preclinical Discovery and Development of the Combination of Ivacaftor + Tezacaftor Used to Treat Cystic Fibrosis","volume":"15","author":"Guerra L.","year":"2020","journal-title":"Expert Opinion on Drug Discovery"},{"issue":"1","key":"e_1_2_7_90_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 Open\u2010Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2\u20105 Years With Cystic Fibrosis and at Least One F508del Allele","volume":"208","author":"Goralski J. L.","year":"2023","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"e_1_2_7_91_1","unstructured":"M. T.Miller C.Anderson V.Arumugam et al. Inventors; Vertex Pharmaceuticals Incorporated assignee. Preparation of N\u2010Aroysulfonamide Derivatives as Cystic Fibrosis Transmembrane Conductance Regulator Modulators. US patent US201600958582016."},{"key":"e_1_2_7_92_1","unstructured":"A. R.Abela T.Alcacio C.Anderson et al. Inventors; Vertex Pharmaceuticals Incorporated assignee. Preparation of N\u2010Heteroaroylsulfonamide Derivatives as Cystic Fibrosis Transmembrane Conductance Regulator Modulators for Treatment of Cystic Fibrosis. US patent WO20181071002018."},{"issue":"8","key":"e_1_2_7_93_1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02171-20","article-title":"New Perspectives on Antimicrobial Agents: Cefiderocol","volume":"65","author":"McCreary E. K.","year":"2021","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"e_1_2_7_94_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40121-020-00286-6","article-title":"Cefiderocol: A Novel Agent for the Management of Multidrug\u2010Resistant Gram\u2010Negative Organisms","volume":"9","author":"Wu J. Y.","year":"2020","journal-title":"Infectious Diseases and Therapy"},{"issue":"12","key":"e_1_2_7_95_1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40262-021-01063-5","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol","volume":"60","author":"Bilal M.","year":"2021","journal-title":"Clinical Pharmacokinetics"},{"key":"e_1_2_7_96_1","unstructured":"Y.Nishitani K.Yamawaki Y.Takeoka H.Sugimoto S.Hisakawa andT.Aoki Inventors; Shionogi & Co. Ltd. assignee. Preparation of Cephalosporins Having Catechol Group as Antibacterial Agents. US patent WO20100504682010."},{"issue":"4","key":"e_1_2_7_97_1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40265-020-01271-6","article-title":"Lumateperone: First Approval","volume":"80","author":"Blair H. A.","year":"2020","journal-title":"Drugs"},{"issue":"12","key":"e_1_2_7_98_1","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3390\/brainsci13121641","article-title":"The Novel Antipsychotic Lumateperone (Iti\u2010007) in the Treatment of Schizophrenia: A Systematic Review","volume":"13","author":"Longo G.","year":"2023","journal-title":"Brain Sciences"},{"issue":"24","key":"e_1_2_7_99_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413289","article-title":"Exploring the Pharmacological and Clinical Features of Lumateperone: A Promising Novel Antipsychotic","volume":"25","author":"Sowa\u2010Ku\u0107ma M.","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"9","key":"e_1_2_7_100_1","article-title":"Illuminating Hope for Mental Health: A Drug Review on Lumateperone","volume":"15","author":"Tarzian M.","year":"2023","journal-title":"Cureus"},{"issue":"6","key":"e_1_2_7_101_1","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1021\/jm401958n","article-title":"Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders","volume":"57","author":"Li P.","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"e_1_2_7_102_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-020-01277-0","article-title":"Osilodrostat: First Approval","volume":"80","author":"Duggan S.","year":"2020","journal-title":"Drugs"},{"issue":"6","key":"e_1_2_7_103_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1159\/000522054","article-title":"Osilodrostat for Cushing Disease and Its Role in Pediatrics","volume":"96","author":"Groselj U.","year":"2022","journal-title":"Hormone Research in Paediatrics"},{"key":"e_1_2_7_104_1","unstructured":"G. M.Ksander E.Meredith L. G.Monovich J.Papillon F.Firooznia andQ.\u2010Y.Hu Inventors; Novartis A.\u2010G. Novartis Pharma G.m.b.H. assignee. Preparation of Condensed Imidazole Derivatives for the Inhibition of Aldosterone Synthase and Aromatase. US patent WO20070249452007."},{"key":"e_1_2_7_105_1","volume-title":"LiverTox: Clinical and Research Information on Drug\u2010Induced Liver Injury","author":"Vibegron","year":"2012"},{"key":"e_1_2_7_106_1","unstructured":"R.Berger L.Chang S. D.Edmondson et al. Inventors; Merck and Co. Inc. assignee. Preparation of Hydroxymethylpyrrolidine Compounds as \u03b23 Adrenergic Receptor Agonists. US patent JP20120209612012."},{"issue":"2","key":"e_1_2_7_107_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-021-01662-3","article-title":"Asciminib: First Approval","volume":"82","author":"Deeks E. D.","year":"2022","journal-title":"Drugs"},{"key":"e_1_2_7_108_1","unstructured":"S. K.Dodd P.Furet R. M.Grotzfeld et al. Inventors; Novartis AG assignee. Preparation of Benzamide Derivatives for Inhibiting the Activity of ABL1 ABL2 and BCR\u2010ABL1 for Treating Cancer. US patent WO20131716392013."},{"issue":"10","key":"e_1_2_7_109_1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40265-023-01895-4","article-title":"Leniolisib: First Approval","volume":"83","author":"Duggan S.","year":"2023","journal-title":"Drugs"},{"key":"e_1_2_7_110_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1337436","article-title":"Leniolisib: A Novel Treatment for Activated Phosphoinositide\u20103 Kinase Delta Syndrome","volume":"15","author":"De S. K.","year":"2024","journal-title":"Frontiers in Pharmacology"},{"issue":"7","key":"e_1_2_7_111_1","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1097\/MS9.0000000000002189","article-title":"Leniolisib: A Drug Providing a Promising Avenue for the Treatment of Activated Phosphoinositide 3\u2010Kinase \u03b4 Syndrome (APDS)","volume":"86","author":"Ali A.","year":"2024","journal-title":"Annals of Medicine & Surgery"},{"key":"e_1_2_7_112_1","unstructured":"P. A.Fernandes Gomes dos Santos K.Hoegenauer G.Hollingworth et al. Inventors; Novartis AG assignee. Preparation of Tetrahydropyrido[4 3\u2010d]Pyrimidine Derivatives for Use as PI3K Enzyme Activity Modulators. US patent WO20130014452013."},{"issue":"7","key":"e_1_2_7_113_1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40265-022-01718-y","article-title":"Pacritinib: First Approval","volume":"82","author":"Lamb Y. N.","year":"2022","journal-title":"Drugs"},{"key":"e_1_2_7_114_1","unstructured":"S.Blanchard C. H. A.Lee H. K. M.Nagaraj et al. Inventors; S*bio Pte Ltd assignee. Preparation of Oxygen Linked Pyrimidine Macrocyclic Derivatives as Antiproliferative Agents. US patent WO20070586272007."},{"issue":"18","key":"e_1_2_7_115_1","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s40265-022-01806-z","article-title":"Futibatinib: First Approval","volume":"82","author":"Syed Y. Y.","year":"2022","journal-title":"Drugs"},{"issue":"20","key":"e_1_2_7_116_1","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-23-1042","article-title":"FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma With FGFR2 Fusions or Other Rearrangements","volume":"29","author":"Gandhy S. U.","year":"2023","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_7_117_1","unstructured":"T.Sagara S.Ito S.Otsuki andH.Sootome Inventors; Taiho Pharmaceutical Co. Ltd. assignee. Preparation of 3 5\u2010Disubstituted Alkynylbenzene Compounds as FGFR Inhibitors. US patent WO20131088092013."},{"issue":"3","key":"e_1_2_7_118_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: First Approval","volume":"83","author":"Dhillon S.","year":"2023","journal-title":"Drugs"},{"issue":"23","key":"e_1_2_7_119_1","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First\u2010In\u2010Human Phase I\/IB Dose\u2010Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL\u20101)","volume":"40","author":"Ou S. H. I.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"e_1_2_7_120_1","article-title":"KRYSTAL\u201012: Phase 3 Study of Adagrasib Versus Docetaxel in Patients With Previously Treated Advanced\/Metastatic Non\u2010Small Cell Lung Cancer (NSCLC) Harboring a KRAS G12C Mutation","volume":"42","author":"Mok T. S. K.","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_7_121_1","unstructured":"J. F.Blake L. E.Burgess M. J.Chicarelli et al. \u201cInventors; Mirati Therapeutics Inc. Array BioPharma Inc. assignee. 5 6 7 8\u2010Tetrahydropyrido[3 4\u2010d]Pyrimidine Derivatives as KRAS G12C Inhibitors and Their Preparation \u201d US patent US201901444442019."},{"key":"e_1_2_7_122_1","unstructured":"M. A.Marx T. P.Bobinski A. C.Burns et al. \u201cInventors; Mirati Therapeutics Inc. Array BioPharma Inc. assignee. Preparation of Pyridopyrimidines as KRAS G12C Inhibitors and Their Preparation \u201d US patent US201902707432019."},{"key":"e_1_2_7_123_1","unstructured":"M. A.Marx T. P.Bobinski A. C.Burns et al. \u201cInventors; Mirati Therapeutics Inc. Array BioPharma Inc. assignee. Dihydropyridopyrimidines as KRAS G12C Inhibitors and Their Preparation \u201d US patent WO20201017362020."},{"issue":"9","key":"e_1_2_7_124_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40265-023-01883-8","article-title":"Trofinetide: First Approval","volume":"83","author":"Keam S. J.","year":"2023","journal-title":"Drugs"},{"key":"e_1_2_7_125_1","unstructured":"P. D.Gluckman G. B.Thomas J.Guan et al. \u201cInventors; Neuren Pharmaceuticals Limited assignee. Effects of Glycyl\u20102 Methyl Prolyl Glutamate on Neurodegeneration \u201d US patent US200702980092007."},{"issue":"5","key":"e_1_2_7_126_1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir Plus Ritonavir: First Approval","volume":"82","author":"Lamb Y. N.","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"e_1_2_7_127_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jpha.2022.10.005","article-title":"Advances and Challenges in Using Nirmatrelvir and Its Derivatives Against SARS\u2010CoV\u20102 Infection","volume":"13","author":"Chen W.","year":"2023","journal-title":"Journal of Pharmaceutical Analysis"},{"key":"e_1_2_7_128_1","unstructured":"D. R.Owen M. Y.Pettersson M. R.Reese et al. Inventors; Pfizer Inc. assignee. Preparation of Peptidomimetic Nitriles as SARS\u2010CoV\u20102 3CL Protease Inhibitors and Methods for the Treatment of COVID\u201019. US patent WO20212506482021."},{"issue":"6","key":"e_1_2_7_129_1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40265-024-02035-2","article-title":"Cefepime\/Enmetazobactam: First Approval","volume":"84","author":"Keam S. J.","year":"2024","journal-title":"Drugs"},{"key":"e_1_2_7_130_1","volume-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Cefepime","year":"2006"},{"issue":"5","key":"e_1_2_7_131_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and Safety of Cefepime: A Systematic Review and Meta\u2010Analysis","volume":"7","author":"Yahav D.","year":"2007","journal-title":"Lancet Infectious Diseases"},{"issue":"6","key":"e_1_2_7_132_1","article-title":"The Trend of Cefepime\u2010Induced Neurotoxicity: A Systematic Review","volume":"15","author":"Ajibola O.","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_7_133_1","unstructured":"A.Alberto D. F.Roberto O.Lauso andS.Doralinda Process for the Direct Preparation of Cefepime for Injectable Use. US patent WO2013114319."},{"issue":"5","key":"e_1_2_7_134_1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40265-024-02023-6","article-title":"Danicopan: First Approval","volume":"84","author":"Kang C.","year":"2024","journal-title":"Drugs"},{"key":"e_1_2_7_135_1","unstructured":"A. P.Phadke A.Hashimoto andM.Andres Inventors; Achillion Pharmaceuticals Inc. assignee. Preparation of Stable Crystalline Forms of Complement Factor D Inhibitors for Therapeutic Use. US patent WO20200690242020."},{"issue":"1","key":"e_1_2_7_136_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.37201\/req\/s01.09.2021","article-title":"Ceftobiprole: A Clinical View","volume":"34","author":"Mart\u00ednez P\u00e9rez\u2010Crespo P. M.","year":"2021","journal-title":"Revista Espa\u00f1ola de Quimioterapia"},{"issue":"8","key":"e_1_2_7_137_1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.clinthera.2024.06.007","article-title":"Ceftobiprole Medocaril Sodium","volume":"46","author":"Beninger P.","year":"2024","journal-title":"Clinical Therapeutics"},{"key":"e_1_2_7_138_1","volume-title":"Ceftobiprole. Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"e_1_2_7_139_1","unstructured":"P.Kremminger J.Ludescher andH.Sturm \u201cInventors; Sandoz AG assignee. Method for the Production of Ceftobiprole Medocaril \u201d US patent WO20101364222010."},{"issue":"18","key":"e_1_2_7_140_1","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s40265-020-01438-1","article-title":"Sofpironium Bromide: First Approval","volume":"80","author":"Paik J.","year":"2020","journal-title":"Drugs"},{"key":"e_1_2_7_141_1","unstructured":"N. S.Bodor \u201cInventor. Soft Anticholinergic Esters \u201d US patent US20120177590A12012."},{"issue":"10","key":"e_1_2_7_142_1","article-title":"Cobenfy (Xanomeline\u2010Trospium Chloride): A New Frontier in Schizophrenia Management","volume":"16","author":"Hasan A. H.","year":"2024","journal-title":"Cureus"},{"issue":"11","key":"e_1_2_7_143_1","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.clinthera.2024.10.001","article-title":"Xanomeline and Trospium Chloride","volume":"46","author":"Beninger P.","year":"2024","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"e_1_2_7_144_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40265-024-02126-0","article-title":"Xanomeline\/Trospium Chloride: First Approval","volume":"85","author":"Syed Y. Y.","year":"2025","journal-title":"Drugs"},{"issue":"2","key":"e_1_2_7_145_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/tcrm.1.2.157.62912","article-title":"Trospium Chloride: An Update on a Quaternary Anticholinergic for Treatment of Urge Urinary Incontinence","volume":"1","author":"Guay D. R.","year":"2005","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"6","key":"e_1_2_7_146_1","first-page":"714","article-title":"On Azoniaspire\u2010Compounds. 1. Preparation of Non\u2010Esterified Azoniaspire\u2010Compounds of nortropan\u20103alpha\u2010 or 3Beta\u2010Ol","volume":"17","author":"Bertholdt H.","year":"1967","journal-title":"Arzneimittel\u2010Forschung"},{"key":"e_1_2_7_147_1","volume-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Vanzacaftor, Tezacaftor and Deutivacaftor","year":"2006"},{"issue":"3","key":"e_1_2_7_148_1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor\u2013Tezacaftor\u2013Deutivacaftor Versus Elexacaftor\u2013Tezacaftor\u2013Ivacaftor in Individuals With Cystic Fibrosis Aged 12 Years and Older (SKYLINE Trials VX20\u2013121\u2010102 and VX20\u2013121\u2010103): Results From Two Randomised, Active\u2010Controlled, Phase 3 Trials","volume":"13","author":"Keating C.","year":"2025","journal-title":"Lancet Respiratory Medicine"},{"key":"e_1_2_7_149_1","unstructured":"P.Angell J. E.Cochran B. J.Littler et al. Inventors; Vertex Pharmaceuticals Incorporated assignee. Process of Making Macrocyclic CFTR Modulators. US patent WO20210305542021."},{"issue":"1","key":"e_1_2_7_150_1","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2025.2479126","article-title":"Topical Delgocitinib for the Treatment of Chronic Hand Eczema","volume":"36","author":"Abdelhalim A.","year":"2025","journal-title":"Journal of Dermatological Treatment"},{"issue":"10","key":"e_1_2_7_151_1","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1097\/MS9.0000000000003771","article-title":"Delgocitinib 2% Cream: A Promising FDA\u2010Approved Therapy for Moderate\u2010To\u2010Severe Chronic Hand Eczema","volume":"87","author":"Jawaid Z.","year":"2025","journal-title":"Annals of Medicine & Surgery"},{"key":"e_1_2_7_152_1","unstructured":"S.Noji M.Shiozaki T.Miura et al. \u201cInventors; Japan Tobacco Inc. assignee. Preparation of Nitrogen\u2010Containing Spiro\u2010Ring Compounds as Janus Kinase (JAK) Kinase Inhibitors \u201d US patent WO 20110137852011."},{"issue":"17","key":"e_1_2_7_153_1","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s40265-023-01959-5","article-title":"Sunvozertinib: First Approval","volume":"83","author":"Dhillon S.","year":"2023","journal-title":"Drugs"},{"issue":"7","key":"e_1_2_7_154_1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/2159-8290.CD-21-1615","article-title":"Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non\u2010Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations","volume":"12","author":"Wang M.","year":"2022","journal-title":"Cancer Discovery"},{"issue":"2","key":"e_1_2_7_155_1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.21037\/tlcr-24-907","article-title":"Sunvozertinib: Shining Light on Lung Cancer's Exon 20 Fight","volume":"14","author":"Mitsudomi T.","year":"2025","journal-title":"Translational Lung Cancer Research"},{"key":"e_1_2_7_156_1","unstructured":"Z.YangandX.Zhang Inventors; Dizal (Jiangsu) Pharmaceutical Co. Ltd. assignee. Aminotriazines and Related Compounds as ErbB\/BTK Inhibitors and Their Preparation. US patent US202302935352023."},{"issue":"6","key":"e_1_2_7_157_1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/13543784.2017.1325872","article-title":"Atrasentan for the Treatment of Diabetic Nephropathy","volume":"26","author":"Egido J.","year":"2017","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"5","key":"e_1_2_7_158_1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1021\/jm9505369","article-title":"2,4\u2010Diarylpyrrolidine\u20103\u2010carboxylic Acids\u2014Potent ETA Selective Endothelin Receptor Antagonists. 1. Discovery of A\u2010127722","volume":"39","author":"Winn M.","year":"1996","journal-title":"Journal of Medicinal Chemistry"}],"container-title":["Medicinal Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.70100","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/med.70100","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.70100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:07:48Z","timestamp":1787116068000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/med.70100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":157,"alternative-id":["10.1002\/med.70100"],"URL":"https:\/\/doi.org\/10.1002\/med.70100","archive":["Portico"],"relation":{},"ISSN":["0198-6325","1098-1128"],"issn-type":[{"value":"0198-6325","type":"print"},{"value":"1098-1128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"2026-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"med.70100"}}